Research programme: immunological disorder therapeutics - Quell Therapeutics
Latest Information Update: 01 Apr 2021
Price :
$50 *
At a glance
- Originator Quell Therapeutics
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Immunological disorders